Cellectis To Participate In Oppenheimer Life Sciences Summit, NY & In Piper Jaffray 28th Annual Health Care Conference, NY

Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that the Company will participate in the upcoming Oppenheimer Life Sciences Summit being held on November 29, 2016 at the Sofitel Hotel in New York City.

Cellectis will be presenting at the Piper Jaffray 28th Annual Health Care Conference. Cellectis presentation will take place on November 30, 2016 at 8:00AM US Eastern Time in Lotte New York Palace - 455 Madison Ave, Track Three - Holmes 1 - 4th Floor.

A live webcast will be available at http://edge.media-server.com/m/p/xbcsg2nz

The replay is available via the same link.

About Cellectis

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 16 years of expertise in genome engineering - based on its flagship TALEN ® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com.

Talking about gene editing? We do it. TALEN ® is a registered trademark owned by the Cellectis Group.


This press release contains "forward-looking" statements that are based on our management's current expectations and assumptions and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The risks and uncertainties include, but are not limited to, the risk that the preliminary results from our product candidates will not continue or be repeated, the risk of not obtaining regulatory approval to commence clinical trials on the UCART product candidates, the risk that any one or more of our product candidates will not be successfully developed and commercialized. Further information on the risks factors that may affect company business and financial performance, is included in filings Cellectis makes with the Security Exchange Commission from time to time and its financial reports. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

If you liked this article you might like

Gene Editing Company Joins NASDAQ, Jumps Over 20% on First Day

As Blue Apron Gets Torn to Shreds, Here Are Upcoming IPOs to Potentially Salvage Your Portfolio

Move Over GMO's: IPO for Gene Editor Calyxt Launches Next Week

Cellectis Gains FDA Nod to Test New Gene-Edited Cancer Treatment

Cellectis Gets FDA Nod to Test New Gene-Edited Cancer Treatment